<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>PRISMA-NMA Checklist</title>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/css/bootstrap.min.css" rel="stylesheet">
  <style>
    body {
      padding-top: 1rem;
      padding-bottom: 1rem;
    }
    .container {
      max-width: 960px;
    }
  </style>
</head>
<body>
  <div class="container">
    <header class="pb-3 mb-4 border-bottom">
      <div class="d-flex align-items-center justify-content-between">
        <div>
          <h1 class="display-4">PRISMA-NMA Checklist</h1>
                  </div>
        <div class="btn-group" role="group">
          <button id="importButton" type="button" class="btn btn-outline-primary">Import</button>
          <button id="exportButton" type="button" class="btn btn-primary">Export</button>
        </div>
      </div>
    </header>

    <div class="progress mb-4">
      <div id="progressBar" class="progress-bar" role="progressbar" style="width: 0%;" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100">0%</div>
    </div>

    <main>
      <h1 id="prisma-nma-checklist">PRISMA-NMA Checklist</h1>
      <h2 id="instructions">Instructions</h2>
      <ul>
      <li>Use the boxes to confirm each reporting item.</li>
      <li>Add reviewer notes under each section as needed.</li>
      </ul>
      <h2 id="title">Title</h2>
      <ul class="task-list">
      <li><label><input type="checkbox" /><strong>1. Title:</strong>
      Identify the report as a systematic review incorporating a network
      meta-analysis (or related form of meta-analysis).</label></li>
      </ul>
      <h2 id="abstract">Abstract</h2>
      <ul class="task-list">
      <li><label><input type="checkbox" /><strong>2. Structured
      Summary:</strong> Provide a structured summary including, as
      applicable:</label>
      <ul>
      <li><strong>Background:</strong> main objectives</li>
      <li><strong>Methods:</strong> data sources; study eligibility
      criteria, participants, and interventions; study appraisal; and
      synthesis methods, such as network meta-analysis.</li>
      <li><strong>Results:</strong> number of studies and participants
      identified; summary estimates with corresponding
      confidence/credible intervals; treatment rankings may also be
      discussed. Authors may choose to summarize pairwise comparisons
      against a chosen treatment included in their analyses for
      brevity.</li>
      <li><strong>Discussion/Conclusions:</strong> limitations;
      conclusions and implications of findings.</li>
      <li><strong>Other:</strong> primary source of funding; systematic
      review registration number with registry name.</li>
      </ul></li>
      </ul>
      <h2 id="introduction">Introduction</h2>
      <ul class="task-list">
      <li><label><input type="checkbox" /><strong>3. Rationale:</strong>
      Describe the rationale for the review in the context of what is
      already known, including mention of why a network meta-analysis
      has been conducted.</label></li>
      <li><label><input type="checkbox" /><strong>4.
      Objectives:</strong> Provide an explicit statement of questions
      being addressed, with reference to participants, interventions,
      comparisons, outcomes, and study design (PICOS).</label></li>
      </ul>
      <h2 id="methods">Methods</h2>
      <ul class="task-list">
      <li><label><input type="checkbox" /><strong>5. Protocol and
      Registration:</strong> Indicate whether a review protocol exists
      and if and where it can be accessed (e.g., Web address); and, if
      available, provide registration information, including
      registration number.</label></li>
      <li><label><input type="checkbox" /><strong>6. Eligibility
      Criteria:</strong> Specify study characteristics (e.g., PICOS,
      length of follow-up) and report characteristics (e.g., years
      considered, language, publication status) used as criteria for
      eligibility, giving rationale. Clearly describe eligible
      treatments included in the treatment network, and note whether any
      have been clustered or merged into the same node (with
      justification).</label></li>
      <li><label><input type="checkbox" /><strong>7. Information
      Sources:</strong> Describe all information sources (e.g.,
      databases with dates of coverage, contact with study authors to
      identify additional studies) in the search and date last
      searched.</label></li>
      <li><label><input type="checkbox" /><strong>8. Search:</strong>
      Present full electronic search strategy for at least one database,
      including any limits used, such that it could be
      repeated.</label></li>
      <li><label><input type="checkbox" /><strong>9. Study
      Selection:</strong> State the process for selecting studies (i.e.,
      screening, eligibility, included in systematic review, and, if
      applicable, included in the meta-analysis).</label></li>
      <li><label><input type="checkbox" /><strong>10. Data Collection
      Process:</strong> Describe method of data extraction from reports
      (e.g., piloted forms, independently, in duplicate) and any
      processes for obtaining and confirming data from
      investigators.</label></li>
      <li><label><input type="checkbox" /><strong>11. Data
      Items:</strong> List and define all variables for which data were
      sought (e.g., PICOS, funding sources) and any assumptions and
      simplifications made.</label></li>
      <li><label><input type="checkbox" /><strong>S1. Geometry of the
      Network:</strong> Describe methods used to explore the geometry of
      the treatment network under study and potential biases related to
      it. This should include how the evidence base has been graphically
      summarized for presentation, and what characteristics were
      compiled and used to describe the evidence base to
      readers.</label></li>
      <li><label><input type="checkbox" /><strong>12. Risk of Bias
      within Individual Studies:</strong> Describe methods used for
      assessing risk of bias of individual studies (including
      specification of whether this was done at the study or outcome
      level), and how this information is to be used in any data
      synthesis.</label></li>
      <li><label><input type="checkbox" /><strong>13. Summary
      Measures:</strong> State the principal summary measures (e.g.,
      risk ratio, difference in means). Also describe the use of
      additional summary measures assessed, such as treatment rankings
      and surface under the cumulative ranking curve (SUCRA) values, as
      well as modified approaches used to present summary findings from
      meta-analyses.</label></li>
      <li><label><input type="checkbox" /><strong>14. Planned Methods of
      Analysis:</strong> Describe the methods of handling data and
      combining results of studies for each network meta-analysis. This
      should include, but not be limited to:</label>
      <ul>
      <li>Handling of multi-arm trials;</li>
      <li>Selection of variance structure;</li>
      <li>Selection of prior distributions in Bayesian analyses;
      and</li>
      <li>Assessment of model fit.</li>
      </ul></li>
      <li><label><input type="checkbox" /><strong>S2. Assessment of
      Inconsistency:</strong> Describe the statistical methods used to
      evaluate the agreement of direct and indirect evidence in the
      treatment network(s) studied. Describe efforts taken to address
      its presence when found.</label></li>
      <li><label><input type="checkbox" /><strong>15. Risk of Bias
      across Studies:</strong> Specify any assessment of risk of bias
      that may affect the cumulative evidence (e.g., publication bias,
      selective reporting within studies).</label></li>
      <li><label><input type="checkbox" /><strong>16. Additional
      Analyses:</strong> Describe methods of additional analyses if
      done, indicating which were pre-specified. This may include, but
      not be limited to, the following:</label>
      <ul>
      <li>Sensitivity or subgroup analyses;</li>
      <li>Meta-regression analyses;</li>
      <li>Alternative formulations of the treatment network;</li>
      <li>Use of alternative prior distributions for Bayesian analyses
      (if applicable).</li>
      </ul></li>
      </ul>
      <h2 id="results">Results</h2>
      <ul class="task-list">
      <li><label><input type="checkbox" /><strong>17. Study
      Selection:</strong> Give numbers of studies screened, assessed for
      eligibility, and included in the review, with reasons for
      exclusions at each stage, ideally with a flow
      diagram.</label></li>
      <li><label><input type="checkbox" /><strong>S3. Presentation of
      Network Structure:</strong> Provide a network graph of the
      included studies to enable visualization of the geometry of the
      treatment network.</label></li>
      <li><label><input type="checkbox" /><strong>S4. Summary of Network
      Geometry:</strong> Provide a brief overview of characteristics of
      the treatment network. This may include commentary on the
      abundance of trials and randomized patients for the different
      interventions and pairwise comparisons in the network, gaps of
      evidence in the treatment network, and potential biases reflected
      by the network structure.</label></li>
      <li><label><input type="checkbox" /><strong>18. Study
      Characteristics:</strong> For each study, present characteristics
      for which data were extracted (e.g., study size, PICOS, follow-up
      period) and provide the citations.</label></li>
      <li><label><input type="checkbox" /><strong>19. Risk of Bias
      within Studies:</strong> Present data on risk of bias of each
      study and, if available, any outcome level
      assessment.</label></li>
      <li><label><input type="checkbox" /><strong>20. Results of
      Individual Studies:</strong> For all outcomes considered (benefits
      or harms), present, for each study: 1) simple summary data for
      each intervention group, and 2) effect estimates and confidence
      intervals. Modified approaches may be needed to deal with
      information from larger networks.</label></li>
      <li><label><input type="checkbox" /><strong>21. Synthesis of
      Results:</strong> Present results of each meta-analysis done,
      including confidence/credible intervals. In larger networks,
      authors may focus on comparisons versus a particular comparator
      (e.g. placebo or standard care), with full findings presented in
      an appendix. League tables and forest plots may be considered to
      summarize pairwise comparisons. If additional summary measures
      were explored (such as treatment rankings), these should also be
      presented.</label></li>
      <li><label><input type="checkbox" /><strong>S5. Exploration for
      Inconsistency:</strong> Describe results from investigations of
      inconsistency. This may include such information as measures of
      model fit to compare consistency and inconsistency models, P
      values from statistical tests, or summary of inconsistency
      estimates from different parts of the treatment
      network.</label></li>
      <li><label><input type="checkbox" /><strong>22. Risk of Bias
      across Studies:</strong> Present results of any assessment of risk
      of bias across studies for the evidence base being
      studied.</label></li>
      <li><label><input type="checkbox" /><strong>23. Results of
      Additional Analyses:</strong> Give results of additional analyses,
      if done (e.g., sensitivity or subgroup analyses, meta-regression
      analyses, alternative network geometries studied, alternative
      choice of prior distributions for Bayesian analyses, and so
      forth).</label></li>
      </ul>
      <h2 id="discussion">Discussion</h2>
      <ul class="task-list">
      <li><label><input type="checkbox" /><strong>24. Summary of
      Evidence:</strong> Summarize the main findings, including the
      strength of evidence for each main outcome; consider their
      relevance to key groups (e.g., healthcare providers, users, and
      policy-makers).</label></li>
      <li><label><input type="checkbox" /><strong>25.
      Limitations:</strong> Discuss limitations at study and outcome
      level (e.g., risk of bias), and at review level (e.g., incomplete
      retrieval of identified research, reporting bias). Comment on the
      validity of the assumptions, such as transitivity and consistency.
      Comment on any concerns regarding network geometry (e.g.,
      avoidance of certain comparisons).</label></li>
      <li><label><input type="checkbox" /><strong>26.
      Conclusions:</strong> Provide a general interpretation of the
      results in the context of other evidence, and implications for
      future research.</label></li>
      </ul>
      <h2 id="funding">Funding</h2>
      <ul class="task-list">
      <li><label><input type="checkbox" /><strong>27. Funding:</strong>
      Describe sources of funding for the systematic review and other
      support (e.g., supply of data); role of funders for the systematic
      review. This should also include information regarding whether
      funding has been received from manufacturers of treatments in the
      network and/or whether some of the authors are content experts
      with professional conflicts of interest that could affect use of
      treatments in the network.</label></li>
      </ul>
      <h3 id="notes">Notes</h3>
      <p><span class="textfield" name="prisma_nma_notes"
      width="12cm">Reviewer notes</span></p>
      <h2 id="provenance">Provenance</h2>
      <ul>
      <li>Source: See sidecar metadata in
      <code>source/variants/prisma-nma.yml</code></li>
      <li>Version: 2015</li>
      <li>License: CC-BY-4.0</li>
      </ul>
    </main>

    <footer class="pt-3 mt-4 text-muted border-top">
      Generated by the standards_check project.
    </footer>
  </div>

  <script src="/assets/js/app.js"></script>
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/js/bootstrap.bundle.min.js"></script>
</body>
</html>
